We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
+7.21%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$166M
AUM Growth
+$16.8M
(+11%)
Cap. Flow
+$19.2M
Cap. Flow
% of AUM
11.58%
Top 10 Holdings %
Top 10 Hldgs %
22.19%
Holding
254
New
38
Increased
43
Reduced
118
Closed
26
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
United Therapeutics
UTHR
|
+$3.61M |
| 2 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
+$3.1M |
| 3 |
Axsome Therapeutics
AXSM
|
+$2.73M |
| 4 |
Pfizer
PFE
|
+$2.64M |
| 5 |
TRML
Tourmaline Bio
TRML
|
+$2.15M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMGN
Immunogen Inc
IMGN
|
+$3.78M |
| 2 |
WBA
Walgreens Boots Alliance
WBA
|
+$3.13M |
| 3 |
ABVX
Abivax
ABVX
|
+$2.86M |
| 4 |
Ironwood Pharmaceuticals
IRWD
|
+$2.8M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
+$2.22M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 61.45% |
| 2 | Real Estate | 11.2% |
| 3 | Financials | 4.6% |
| 4 | Industrials | 3.92% |
| 5 | Technology | 2.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Royalty Pharma
RPRX
$25.9B
| $1.82M | 1.1% |
60,000
+20,000
| +50% | +$590K |
|
|
CERE
27
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $1.8M | 1.08% |
42,500
+17,500
| +70% | +$735K |
|
28
Medtronic
MDT
$107B
| $1.79M | 1.08% |
20,500
| – | – |
|
29
Karyopharm Therapeutics
KPTI
$178M
| $1.7M | 1.02% |
75,000
| – | – |
|
30
Celldex Therapeutics
CLDX
$2.79B
| $1.62M | 0.97% |
+38,500
| New | +$1.58M |
|
31
Invesco S&P 500 Pure Value ETF
RPV
$1.6B
| $1.58M | 0.95% |
+17,834
| New | +$1.48M |
|
32
Stereotaxis
STXS
$153M
| $1.57M | 0.94% |
600,000
| – | – |
|
33
iShares Russell 1000 Value ETF
IWD
$81.7B
| $1.55M | 0.94% |
+8,671
| New | +$1.47M |
|
|
KALV
34
DELISTED
KalVista Pharmaceuticals
KALV
| $1.54M | 0.93% |
130,000
-7,000
| -5% | -$93.3K |
|
|
DVAX
35
DELISTED
Dynavax Technologies
DVAX
| $1.52M | 0.92% |
122,500
+22,500
| +23% | +$293K |
|
36
GSK
GSK
$102B
| $1.5M | 0.91% |
35,000
| – | – |
|
|
BCYC
37
Bicycle Therapeutics
BCYC
$291M
| $1.49M | 0.9% |
+60,000
| New | +$1.27M |
|
38
ArriVent BioPharma
AVBP
$1.48B
| $1.48M | 0.89% |
+83,000
| New | +$1.67M |
|
39
Embecta
EMBC
$198M
| $1.48M | 0.89% |
111,500
-88,500
| -44% | -$1.37M |
|
40
Viking Therapeutics
VKTX
$4.31B
| $1.48M | 0.89% |
+18,000
| New | +$801K |
|
|
ADAM
41
Adamas Trust
ADAM
$799M
| $1.45M | 0.87% |
200,963
| – | – |
|
42
Synopsys
SNPS
$72B
| $1.43M | 0.86% |
2,500
+400
| +19% | +$220K |
|
|
TRML
43
DELISTED
Tourmaline Bio
TRML
| $1.4M | 0.84% |
+61,100
| New | +$2.15M |
|
|
ITCI
44
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $1.38M | 0.83% |
20,000
| – | – |
|
45
VYNE Therapeutics
VYNE
$27M
| $1.37M | 0.82% |
445,000
-223,151
| -33% | -$481K |
|
46
BioMarin Pharmaceuticals
BMRN
$11.5B
| $1.35M | 0.82% |
15,500
+1,500
| +11% | +$134K |
|
47
Equity Lifestyle Properties
ELS
$12.7B
| $1.33M | 0.8% |
20,611
| – | – |
|
48
Enact Holdings
ACT
$6.51B
| $1.32M | 0.8% |
42,367
| – | – |
|
|
MITT
49
TPG Mortgage Investment Trust
MITT
$242M
| $1.28M | 0.77% |
208,879
| – | – |
|
50
Procept Biorobotics
PRCT
$1.07B
| $1.24M | 0.75% |
+25,000
| New | +$1.19M |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q1 2024 Portfolio in Review
As of Q1 2024, AlphaCentric Advisors held 254 positions worth $166M, up 11% from $149M the previous quarter. Its ten largest holdings account for 22% of the portfolio.
AlphaCentric Advisors deployed $19.2M of net new capital in Q1 2024, opening 38 new positions and adding to 43 existing holdings. Its largest new stake was United Therapeutics: 16,000 shares worth $3.68M.
By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 59% a quarter earlier, followed by Real Estate and Financials.
On the sell side, the largest reduction was Invesco NASDAQ 100 ETF, an estimated $1.72M trimmed.
- AlphaCentric Advisors's largest Q1 2024 buy was United Therapeutics: 16,000 shares worth $3.68M.
- AlphaCentric Advisors added most to Inari Medical, Inc. Common Stock in Q1 2024, an estimated $3.1M increase.
- AlphaCentric Advisors's biggest Q1 2024 reduction was Invesco NASDAQ 100 ETF, cutting an estimated $1.72M.
- AlphaCentric Advisors fully exited Immunogen Inc in Q1 2024, selling an estimated $3.78M.
- AlphaCentric Advisors's ten largest holdings make up 22% of its $166M portfolio in Q1 2024.
- AlphaCentric Advisors opened 38 new positions and closed 26 in Q1 2024.
- AlphaCentric Advisors's portfolio value rose 11% quarter-over-quarter to $166M.
Based on AlphaCentric Advisors's 13F filing for Q1 2024, filed 24 Apr 2024.